吉林治早泄有哪些地方吉林哪里切割包皮好,吉林在正规医院看前列腺多少钱,吉林现在包皮包茎哪家医院好,吉林包皮有红点,吉林早泄要花多少钱才能治好,吉林男性阳萎早泄的医院治疗,吉林包皮过长那些症状

COPENHAGEN, April 30 (Xinhua) -- As traditional Chinese medicine (known as TCM in Europe) becomes increasingly popular worldwide and has gradually been regarded as a useful component to Western medical treatments, Denmark is no stranger to such trends.According to a study published by the University of Copenhagen in mid-Feb., up to one-third of Danish hospitals choose complementary or alternative therapies, including TCM methods, to treat pain, cancer, mental disease, tumors and infertility. Acupuncture remains the most widely-practiced form of these treatments, used in some 97 percent of the cases.The nationwide acceptance of acupuncture and massage therapists, the growing ranks of herbal practitioners, and the hosting of an annual pan-Scandinavian TCM conference since 2007, all underline the popularity of alternative medicine, including the TCM, in the country.However, the overall market presence of TCM, and herbal medicines in particular, is relatively small in Denmark and Europe at large. As many European policymakers insist that traditional herbal medicines "are neither scientifically documented nor tested according to Western requirements," these treatments face difficulties in obtaining licenses and boosting sales in Europe.In fact, despite their historical pedigree and widely-accepted efficacy, TCM products are often classified as "healthcare products" or "food," rather than "drugs" in European markets.A big challenge for TCM products to gain more access to the continent is the EU's Traditional Herbal Medicinal Products Directive, which stipulates that all such products must obtain authorization if they are to be sold within the EU, starting May 1, 2011.The directive says producers must prove the product in question has been used for 30 years, 15 of which within the EU, so as to ensure its safety.While licensing is expected to be onerous and expensive, Denmark has tried to bring TCM products into the Western medical mainstream from as early as 2005. The country's well-developed biochemical and medical industry, modernized agriculture and horticulture sectors and a strong track record of cooperative research in these fields, has helped TCM's cause.For instance, Traditional Complementary Medicine Denmark, a company helping herbal product makers market their goods in Western countries, uses modern biotechnology processes and clinical trials to scientifically verify and document the efficacy of existing herbal medicines.It also advises herbal product makers on how to align their standards with European requirements so as to acquire the necessary sales licenses. Sometimes, simple solutions like clearer and more detailed labeling of a TCM product's ingredients can help improve its marketability. Patent applications and drug approvals procedures must follow, before the product can access the EU pharmaceutical market, usually in pill form.Investing in herbal medicine also makes financial sense for Denmark, as it is encourages development of low-bulk, high-value agricultural products, which can be easily transported all over the globe.Development Centre Aarslev, a Danish agro-research body and partner of TCM Denmark, studies the active ingredients contained in medicinal plants and their impact on human health conditions such as cardiovascular problems, diabetes and allergies. One of the earliest collaborations it undertook with a producer of herbal medicine showed the effectiveness of extracts from the hips of the dog rose plant in treating rheumatoid arthritis.A spokesperson for the institution said, "We have documented analytical evidence which shows that arthritis patients can reduce their consumption of conventional anti-arthritis drugs by up to 50 percent, if they combine them with the herbal drug based on dog rose hips."Given Denmark's population of 5.5 million people, this could translate into savings of 200 million U.S. dollars a year on anti-arthritis medication, the spokesperson added.Other plant-based interventions could hold wider public health benefits. TCM practitioners say herbal medicines can improve blood circulation in humans, and contain naturally-occurring antioxidants which can reduce the risks of heart attacks and better regulate cardiovascular functions. This has potentially wide-ranging benefit for Western societies, where heart disease is a major threat.Heart disease was the most common cause of death in Denmark until 2000, and cardiovascular disease the commonest until 2008, with cancer now ranking the biggest killer.In fact, TCM herbal remedies are also considered a good choice for cancer treatment, as certain plants contain hormone-like substance which can influence hormone-dependent cancers, such as breast and prostate cancer.TCM supporters say the obvious benefit of such an intervention is the avoidance of more commonly-used chemotherapy and radiation treatments which often produce severe side-effects in patients. Relevant herbal therapies can help strengthen cancer patient's immune system, reduce side-effects of chemotherapy and radiation therapy, and alleviate other symptoms of the disease.Given the many potential benefits of TCM, the EU's tightening of rules may appear harsh. Still, TCM is considered a relatively novel approach to medicine in Europe. Moreover, the dominant market share and general clout of the chemical-based, Western pharmaceutical industry also makes it difficult for traditional remedies to stake their claim.

WASHINGTON, April 11 (Xinhua) -- Taking a statin before having major elective surgery reduces potentially serious kidney complications, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology.Each year, more than 230 million major elective surgeries are performed around the world. Unfortunately, many patients who undergo major operations develop kidney injury soon after surgery, often due to decreased blood flow to the kidneys and/or the effects of inflammation.Animal studies suggest that the cholesterol-lowering drugs called statins protect the kidneys from such damage, but whether a similar benefit occurs in humans is uncertain. To investigate, Amber Molnar, University of Western Ontario, and colleagues conducted a population-based retrospective study of all older patients who underwent major elective surgery in the province of Ontario, Canada from 1995 to 2008. Surgeries included cardiac, thoracic, vascular, intra-abdominal, and retroperitoneal procedures.A total of 213,347 patients from 211 hospitals underwent major elective surgery, and 4,020 patients (1.9 percent) developed postoperative kidney injury within two weeks of surgery. A total of 1,173 patients (0.5 percent) required dialysis within two weeks of surgery, and 5,974 patients (2.8 percent) died within a month of surgery.Prior to surgery, 67,941 patients (32 percent) were taking a statin. Patients taking a statin were 20 percent less likely to develop kidney injury, need dialysis, and die compared to patients who were not taking a statin. Also, there was evidence of a dose-effect, with patients on higher potency statins having less kidney injury. In addition, statins were beneficial whether they were started greater than 90 days or less than 30 days prior to surgery."Our study suggests that statin use in older persons results in less kidney injury following major elective surgery and reduces the risk of premature death after surgery," said Molnar, adding that the results warrant further investigation with more rigorous studies, but such trials will be difficult to carry out.

BEIJING, March 8 (Xinhuanet) -- U.S. Food and Drug Administration (FDA) announced there was no new reason for safety concern in Pfizer Inc's Prevenar and Sanofi Aventis SA's ActHIBor vaccines, according to media reports Tuesday.Health agencies "have not detected new safety concerns or unusual reporting patterns" in the vaccines, which are used to prevent forms of meningitis and pneumonia, FDA spokeswoman Shelly Burgess said in an emailed statement.Health agencies in the United States will continue to monitor the vaccines for safety, the spokeswoman added.The Japanese health ministry had decided to suspend the vaccines after four unexplained deaths were reported. The causes of the deaths are still investigated, the Japanese ministry said in a release on its website.

DAVOS, Switzerland, Jan. 27 (Xinhua) -- A policy of more trade and greater openness to the rest of the world has brought significant benefits to China and greater market opportunities to its trading partners, the head of the World Trade Organization says."I don't think there is any question that China joining the WTO has been a very good thing for China and for the WTO and its members," WTO Director General Pascal Lamy said in an interview with Xinhua.The WTO chief was expected to join the forum "China's Impact on Global Trade and Growth" on the sidelines of the World Economic Forum annual meeting held in this Swiss alpine town."In joining the WTO, China successfully underpinned a policy of what had been 20 years of progressive openness," Lamy said.Adherence to economic reforms through international commitments ensured that China would stay on the path of openness, he noted, adding that the policy has helped the country economically, politically and socially.Lamy stressed that China has done a "remarkable job" in reducing poverty, which is an important task for the country, along with registering double-digit growth, thus becoming the world's largest manufacturer and the second largest economy.Apart from enhanced market access with its trading partners and more equal treatment in global trade, WTO membership also has allowed China to gain access to the organization's dispute settlement system, Lamy said.According to a WTO report issued in December, as the world's biggest exporter, China ranks first in receiving anti-dumping (AD) investigations, with 23 new AD initiations directed at its exports in the first half of 2010.In recent rulings arbitrated by the WTO Dispute Settlement Body (DSB), China has won a poultry dispute against the United States, and a steel fastener case against the European Union.Being a WTO member, "China would have a seat at the table as negotiations commenced on the trade rules for the 21st century," Lamy said, referring to the decade-long Doha round of global trade negotiations aimed at building the next generation trading system.Even more importantly, for China, participation in the global system of rules and discipline greatly boosted investors' confidence and helped facilitate foreign direct investment in China, he said.On the other side of the coin, China's integration into the world trading system has given enormous driving force to the global economy and market opportunity to its trade partners.